All In Biotech

Free tool

FAERS Monitor: Tobi Podhaler

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 201688 or its brand name (Tobi Podhaler, Tobramycin). Reports on generic versions are filed under their own applications.

Reports

15,248

Serious

12,015

79% of reports

Hospitalization

7,351

Death reported

1,542

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • dyspnoea931
  • pneumonia927
  • off label use899
  • cough847
  • infective pulmonary exacerbation of cystic fibrosis842
  • cystic fibrosis778
  • condition aggravated743
  • drug ineffective742
  • death717
  • acute kidney injury691
  • hospitalisation691
  • infection511
  • pyrexia495
  • fatigue451
  • malaise450

Reports by year received

View as table
YearReports
200480
200597
200676
2007124
200890
200999
2010101
2011208
2012213
2013288
2014659
20151,050
2016857
2017736
20181,177
20191,878
20201,727
20211,152
20221,047
2023883
20241,087
2025925
2026694

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,038,911 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
infective pulmonary exacerbation of cystic fibrosisSignal842252.2234.8177,968
cystic fibrosisSignal778225.3209.2149,208
acute kidney injurySignal6916.35.83,052
hospitalisationSignal6916.25.83,035
infectionSignal5114.94.51,580
coughSignal8474.23.92,064
pneumoniaSignal9274.03.72,072
condition aggravatedSignal7433.43.11,256
dyspnoeaSignal9312.32.1678
pyrexia4952.01.8241
off label use8991.41.3114
malaise4501.41.356
death7171.11.114
fatigue4510.80.723
drug ineffective7420.80.751

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.